🔗 Share this article

The recently developed medications for gonorrhoea in decades are being viewed as a "major milestone" in the effort against drug-resistant strains of the pathogen, according to scientists.

An International Challenge

Gonorrhoea infections are increasing globally, with figures suggesting more than 82 million infections annually. Notably increased rates are observed in Africa and nations within the WHO's Western Pacific region, which includes Mongolia and China to New Zealand. Within England, cases have hit a all-time high, while infection numbers across Europe in 2023 were significantly elevated compared to figures for 2014.

“The authorization of new treatments for gonorrhoea is an significant and necessary development in the reality of growing infection rates, the spread of superbugs and the very limited therapeutic options currently available.”

Public health authorities are deeply concerned about the increase in antibiotic-resistant strains. The WHO has listed it as a "high-priority threat". Recent surveillance revealed that resistance to primary antibiotics like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

Two New Drugs Receive Clearance

One new antibiotic, marketed under the name a brand name, was cleared by the US Food and Drug Administration in mid-December for combating gonorrhoea. This disease can lead to significant complications, including the inability to conceive. Researchers believe that targeted use of this new drug will help slow the spread of drug resistance.

Gepotidacin, originating from the drugmaker GlaxoSmithKline, was also approved in the same week. This treatment, which is employed against urinary tract infections, was proven in research to be able to combat drug-resistant strains of the gonorrhoea bacteria.

An Innovative Approach to Creation

This new treatment emerged from a new, not-for-profit approach for medication research. The non-profit organisation GARDP worked alongside the drug firm Innoviva to develop it.

“This approval represents a major breakthrough in the treatment of superbug gonorrhoea, which previously has been outpacing antibiotic development.”

Testing Data and Global Access

According to findings released by a major medical journal, zoliflodacin successfully treated the vast majority of cases of the STI. This establishes an similar efficacy with the typical regimen, which uses a dual-drug approach. The study enrolled hundreds of patients from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its collaboration, GARDP has the authority to license and sell the drug in a wide range of regions with limited resources.

Doctors directly involved have voiced positive views. Access to a easy-to-administer therapy such as this is seen as a "game-changer" for managing the epidemic. This is considered vital to alleviate the strain of the infection for individuals and to prevent the spread of untreatable gonorrhoea globally.